Trial Profile
A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms KEYNOTE-789
- Sponsors Merck Sharp & Dohme Corp.
- 10 Oct 2023 Status changed from active, no longer recruiting to completed.
- 08 Aug 2023 Planned End Date changed from 15 Jun 2023 to 2 Oct 2023.
- 06 Jun 2023 Primary endpoint (Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)) has not been met according to Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.